Prognostic Implications of HER-2 Status in Steroid Receptor–Positive, Lymph Node–Negative Breast Carcinoma
Open Access
- 1 May 2007
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 127 (5) , 780-786
Abstract
Patients with lymph node–negative breast carcinoma (LNNBC) and positive hormone receptor (HR) status during estrogen-based endocrine therapy have difKeywords
This publication has 21 references indexed in Scilit:
- Early growth response gene 1 (EGR1) is deleted in estrogen receptor‐negative human breast carcinomaCancer, 2005
- Association of TNF-α and TNF-β gene polymorphism with steroid receptor expression in breast cancer patientsPathology and Oncology Research, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Hormone receptor status and survival in a population‐based cohort of patients with breast carcinomaCancer, 2005
- The role of progesterone metabolites in breast cancer: Potential for new diagnostics and therapeuticsThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Progesterone Receptor Contains a Proline-Rich Motif that Directly Interacts with SH3 Domains and Activates c-Src Family Tyrosine KinasesMolecular Cell, 2001
- Biology of HER2 and Its Importance in Breast CancerOncology, 2001
- c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER +) breast cancer patients with poor prognosisAnnals of Oncology, 2001
- c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced diseaseEuropean Journal of Cancer, 2001
- Steroid hormone receptors in breast cancer managementBreast Cancer Research and Treatment, 1998